Connection

Cristina Gervasoni to HIV Infections

Back to Details
This is a "connection" page, showing publications Cristina Gervasoni has written about HIV Infections.
Cristina Gervasoni
Connection Strength
2.684
HIV Infections
  1. Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". Clin Pharmacokinet. 2021 06; 60(6):829-831.
    View in: PubMed
    Score: 0.144
  2. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021 05; 22(5):372-378.
    View in: PubMed
    Score: 0.141
  3. Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2276-2278.
    View in: PubMed
    Score: 0.140
  4. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
    View in: PubMed
    Score: 0.134
  5. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. Eur J Drug Metab Pharmacokinet. 2019 Jun; 44(3):319-327.
    View in: PubMed
    Score: 0.126
  6. Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res. 2019 07; 145:104267.
    View in: PubMed
    Score: 0.126
  7. Different effects of glucocorticoids on darunavir plasma concentrations. Eur J Clin Pharmacol. 2019 May; 75(5):733-735.
    View in: PubMed
    Score: 0.123
  8. Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic AIDS Rev. 2019; 21(1):40-49.
    View in: PubMed
    Score: 0.123
  9. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World J Biol Psychiatry. 2020 10; 21(8):651-657.
    View in: PubMed
    Score: 0.120
  10. How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life? J Antimicrob Chemother. 2018 08 01; 73(8):2271-2273.
    View in: PubMed
    Score: 0.119
  11. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution? Obesity (Silver Spring). 2018 08; 26(8):1251-1252.
    View in: PubMed
    Score: 0.119
  12. Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction? AIDS. 2018 02 20; 32(4):532-533.
    View in: PubMed
    Score: 0.116
  13. Psychoactive drugs and HIV: are we sure to treat our patients adequately? AIDS. 2018 01 02; 32(1):127-128.
    View in: PubMed
    Score: 0.115
  14. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
    View in: PubMed
    Score: 0.115
  15. The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. Antivir Ther. 2018; 23(5):467-469.
    View in: PubMed
    Score: 0.115
  16. Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. Eur J Drug Metab Pharmacokinet. 2017 Aug; 42(4):559-572.
    View in: PubMed
    Score: 0.111
  17. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
    View in: PubMed
    Score: 0.110
  18. How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life? J Acquir Immune Defic Syndr. 2017 05 01; 75(1):e24-e26.
    View in: PubMed
    Score: 0.109
  19. Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. AIDS. 2017 03 27; 31(6):867-868.
    View in: PubMed
    Score: 0.109
  20. Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring. Antivir Ther. 2017; 22(4):361-363.
    View in: PubMed
    Score: 0.107
  21. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
    View in: PubMed
    Score: 0.107
  22. Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Ther Drug Monit. 2019 02; 41(1):59-65.
    View in: PubMed
    Score: 0.031
  23. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):193-201.
    View in: PubMed
    Score: 0.029
  24. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
    View in: PubMed
    Score: 0.029
  25. Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons. AIDS Rev. 2017 Oct-Dec; 19(3):167-172.
    View in: PubMed
    Score: 0.028
  26. The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
    View in: PubMed
    Score: 0.027
  27. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002 Dec 9-23; 162(22):2621-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.